logo-loader

Willow Biosciences poised to be the first company to commercially produce CBG, the "mother of all cannabinoids"

Last updated: 08:33 01 Mar 2024 EST, First published: 14:45 15 Dec 2021 EST

Snapshot

  • Willow Biosciences unveils second strategic investment from Kalsec
  • Willow Bioscience announces unique collaboration with Enterin Inc
Willow Biosciences Inc. -

About the company

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers. For more information, visit www.willowbio.com.

How it is doing

01 Mar 2024

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced that Kalsec, a leading global producer of food protection, colors, and advanced hop products for the food and beverage industry, has made a second strategic investment in the company.

The company said this investment was connected to a previous one, where Kalsec committed to subscribe for an additional US$100,000 upon the completion of an operational milestone by Willow, which was completed on February 23.

The proceeds from the investment will be used for the commercialization and development of Willow’s pipeline of products, including natural food ingredients, working capital, and general corporate purposes.

Per the terms of the investment, the company issued 1,153,131 units at C$0.12 each.

21 Feb 2024

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a strategic US$100,000 investment from Kalsec Inc to aid its development and commercialization of natural food ingredients.

Updating on Tuesday, Willow said the non-brokered private equity placement was expected to mark the first tranche of financing based on development milestones.

31 Jan 2024

Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a collaboratiion with a leading Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable and cost-effective manufacturing process for their largest product.

The company said that its partner had recognized it needed to deploy more sustainable methods to manufacture its APIs with reduced cost and waste and engaged Willow to develop and scale a manufacturing route for this key ingredient, focusing on optimization of the existing commercial biomanufacturing process for improved performance at scale.

What management says

17 Jan 2024

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has announced they plan to collaborate with Enterin, which is a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to develop new sustainable manufacturing routes to its key intermediates and active pharmaceutical ingredients or API’s.

Savile told Proactive Enterin recognized the need to employ more sustainable methods to manufacture its key development targets at reduced cost and less waste and sought Willow's expertise in developing and scaling biobased processes. The initial program will focus on the feasibility of developing a biobased pathway and, if successful, advance development toward implementation at commercial scale. The development phase of this funded collaboration is expected to last approximately three months. In 2024, the company aims to transition its research and development programs into commercial revenue, emphasizing the execution of commercial agreements, advancing technology, and expanding its innovator partnerships.

Savile underscored the goal of achieving these milestones without increasing overhead. The interview reflects Willow Biosciences' commitment to strategic growth and transformative solutions in the biotechnology sector. Stay tuned for more exciting developments from this innovative company led by Dr. Chris Savile, shaping the future of bioscience.

Willow Bioscience announces unique collaboration with Enterin Inc

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to share news the company has announced they plan to collaborate with Enterin, which is a clinical stage biopharmaceutical company pioneering novel treatments that target neurodegenerative and metabolic disorders, to...

on 01/17/2024